ReviewPathogens (Basel, Switzerland)2021
Review in Pathogens (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 15 citations in OpenAlex.
- Liposomal Glutathione Exhibits Direct and Intracellular Antimycobacterial Activity AgainstBioengineering (Basel, Switzerland) · 2026Article
- Non-Tuberculous Mycobacteria at the Human-Animal-Environment Interface: Antimicrobial Resistance, Environmental Persistence and Cross-Species Exposure Risks.Antibiotics (Basel, Switzerland) · 2026Review
- Current perspectives on avian tuberculosis in domestic and wild birds: Molecular diagnostics, genomic surveillance, and vaccination challenges.Open veterinary journal · 2026Review
- Novel nucleoside analogs exhibit potent intracellular andMicrobiology spectrum · 2026Article
- Isolation and Molecular Identification of Potentially Pathogenic Free-Living Amoeba in Tap Water Faucets in Quezon City, Philippines.Journal of parasitology research · 2026Article
- Article
- Analysis of nontuberculous mycobacterial infections in Saudi children from a tertiary care hospital perspective.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- Encapsulin protein MAV2054 enhances Mycobacterium avium virulence by promoting Cdc42-dependent epithelial cell invasion.Journal of microbiology (Seoul, Korea) · 2025Article
- Genetic Factors ofPathogens (Basel, Switzerland) · 2025Article
- Targeting Autophagy as a Strategy for Developing New Host-Directed Therapeutics Against Nontuberculous Mycobacteria.Pathogens (Basel, Switzerland) · 2025Review
- Review
- E3 ubiquitin ligase CBLB regulates innate immune responses and bacterial dissemination during nontuberculous mycobacteria infection.Journal of leukocyte biology · 2024Article
- MptpB Inhibitor Improves the Action of Antibiotics againstACS infectious diseases · 2024Article
- InvestigatingMicrobiology spectrum · 2023Article
- Metabolic pathways that permitFrontiers in cellular and infection microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-tuberculosis mycobacteria (NTM) are ubiquitously found throughout the environment. NTM can cause respiratory infections in individuals with underlying lung conditions when inhaled, or systemic infections when ingested by patients with impaired immune systems. Current therapies can be ineffective at treating NTM respiratory infections, even after a long course or with multidrug treatment regimens. NTM, such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.